These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
118 related items for PubMed ID: 17704745
1. Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro. Yerushalmi R, Nordenberg J, Beery E, Uziel O, Lahav M, Luria D, Fenig E. Exp Oncol; 2007 Jun; 29(2):126-31. PubMed ID: 17704745 [Abstract] [Full Text] [Related]
2. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro. Wang-Rodriguez J, Lopez JP, Altuna X, Chu TS, Weisman RA, Ongkeko WM. Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745 [Abstract] [Full Text] [Related]
3. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition. Te Kronnie G, Timeus F, Rinaldi A, Crescenzio N, Spinelli M, Rosolen A, Ricotti E, Basso G. Int J Mol Med; 2004 Sep; 14(3):373-82. PubMed ID: 15289888 [Abstract] [Full Text] [Related]
4. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate. Shaw TJ, Vanderhyden BC. Gynecol Oncol; 2007 Apr; 105(1):122-31. PubMed ID: 17169414 [Abstract] [Full Text] [Related]
5. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. Scotlandi K, Manara MC, Strammiello R, Landuzzi L, Benini S, Perdichizzi S, Serra M, Astolfi A, Nicoletti G, Lollini PL, Bertoni F, Nanni P, Picci P. J Clin Oncol; 2003 May 15; 21(10):1952-60. PubMed ID: 12743148 [Abstract] [Full Text] [Related]
6. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling. Weigel MT, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Bauer M, Jonat W, Maass N, Mundhenke C. Cancer Lett; 2009 Jan 08; 273(1):70-9. PubMed ID: 18809244 [Abstract] [Full Text] [Related]
7. c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571). Hotfilder M, Lanvers C, Jürgens H, Boos J, Vormoor J. Cancer Chemother Pharmacol; 2002 Aug 08; 50(2):167-9. PubMed ID: 12172985 [Abstract] [Full Text] [Related]
8. Anti-proliferative activity of haloperidol in B16 mouse and human SK-MEL-28 melanoma cell lines. Nordenberg J, Perlmutter I, Lavie G, Beery E, Uziel O, Morgenstern C, Fenig E, Weizman A. Int J Oncol; 2005 Oct 08; 27(4):1097-103. PubMed ID: 16142328 [Abstract] [Full Text] [Related]
9. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines. Noma K, Naomoto Y, Gunduz M, Matsuoka J, Yamatsuji T, Shirakawa Y, Nobuhisa T, Okawa T, Takaoka M, Tomono Y, Hiroyuki O, Gunduz E, Tanaka N. Oncol Rep; 2005 Sep 08; 14(3):645-50. PubMed ID: 16077968 [Abstract] [Full Text] [Related]
10. In vitro test-system for chemo- and thermosensitivity: an analysis of survival fractions and cell-cycle distributions in human Ewing's sarcomas as a modelfor tumors in pediatric oncology. Debes A, Rommel F, Breise M, Willers R, Göbel U, Wessalowski R. Klin Padiatr; 2002 Sep 08; 214(4):223-9. PubMed ID: 12165906 [Abstract] [Full Text] [Related]
11. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line. Sawada S, Mese H, Sasaki A, Yoshioka N, Matsumura T. Cancer Chemother Pharmacol; 2003 Jun 08; 51(6):505-11. PubMed ID: 12709826 [Abstract] [Full Text] [Related]
12. Effect of epidermal growth factor receptor inhibitor alone and in combination with cisplatin on growth of vulvar cancer cells. Kim SH, Song YC, Kim SH, Jo H, Song YS. Ann N Y Acad Sci; 2009 Aug 08; 1171():642-8. PubMed ID: 19723115 [Abstract] [Full Text] [Related]
13. Synergistic effect of combining paeonol and cisplatin on apoptotic induction of human hepatoma cell lines. Xu SP, Sun GP, Shen YX, Peng WR, Wang H, Wei W. Acta Pharmacol Sin; 2007 Jun 08; 28(6):869-78. PubMed ID: 17506946 [Abstract] [Full Text] [Related]
14. Potential role of imatinib mesylate (Gleevec, STI-571) in the treatment of vestibular schwannoma. Altuna X, Lopez JP, Yu MA, Arandazi MJ, Harris JP, Wang-Rodriguez J, An Y, Dobrow R, Doherty JK, Ongkeko WM. Otol Neurotol; 2011 Jan 08; 32(1):163-70. PubMed ID: 21157293 [Abstract] [Full Text] [Related]
15. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Zhang P, Gao WY, Turner S, Ducatman BS. Mol Cancer; 2003 Jan 03; 2():1. PubMed ID: 12537587 [Abstract] [Full Text] [Related]
17. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study. Martins AS, Ordoñez JL, García-Sánchez A, Herrero D, Sevillano V, Osuna D, Mackintosh C, Caballero G, Otero AP, Poremba C, Madoz-Gúrpide J, de Alava E. Cancer Res; 2008 Aug 01; 68(15):6260-70. PubMed ID: 18676850 [Abstract] [Full Text] [Related]
18. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro. Liu H, Zang C, Schefe JH, Schwarzlose-Schwarck S, Regierer AC, Elstner E, Schulz CO, Scholz C, Possinger K, Eucker J. Anticancer Res; 2011 Sep 01; 31(9):2713-22. PubMed ID: 21868512 [Abstract] [Full Text] [Related]
19. Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines. Yokoyama T, Miyazawa K, Yoshida T, Ohyashiki K. Int J Oncol; 2005 Jan 01; 26(1):33-40. PubMed ID: 15586222 [Abstract] [Full Text] [Related]
20. Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells. Foroodi F, Duivenvoorden WC, Singh G. Anticancer Drugs; 2009 Feb 01; 20(2):115-22. PubMed ID: 19209028 [Abstract] [Full Text] [Related] Page: [Next] [New Search]